I. Roziner (Tel Aviv, Israel)

Sackler Faculty of Medicine, Tel Aviv University

Author Of 1 Presentation

 On-Demand ePoster Display

132P - The psychological impact of the COVID-19 pandemic on patients with early breast cancer

Abstract

Background

Direct impact of the COVID-19 pandemic, in addition to the measures adopted to control its spread, may cause a significant emotional burden, especially in patients with cancer. This study aims to understand the psychological impact of COVID-19 pandemic on patients with early breast cancer.

Methods

The BOUNCE study, assessing, among others, depression and anxiety symptoms, has a longitudinal design and includes early breast cancer patients across 3 European countries and Israel. The study was ongoing when the COVID-19 pandemic started in Europe and data collection has continued, allowing for measurements of associations between symptom severity in three time points and COVID-related parameters (CRP) retrieved from a publicly available database (Our World in Data). Descriptive statistics and series of multilevel mixed-effects linear regression models were performed to assess variation in individual level symptom severity as a function of country-level COVID-19 pandemic parameters across time.

Results

Among 724 participants included in the analyses, 307 were exposed to the pandemic. For depressive symptoms, anxiety symptoms and general psychological distress, we did not find statistically significant associations with weekly COVID-19 incidence, weekly COVID-19 death rate or weekly stringency level of government-imposed COVID-19 containment measures. For depressive symptoms only, we found statistically significant negative interactions with time for COVID-19 incidence (β= −0.002, SE=0.001, p=0.04) and containment measures (β= −0.001, SE=0.001, p=0.02), that we are currently exploring in further analyses.

Conclusions

In women with early breast cancer across 3 European countries and Israel, country-wide CRPs did not seem to have a significant psychological impact, namely regarding to symptoms of depression and anxiety. Given the continuing nature of the pandemic, we will continue the data collection, including more time points of assessment to evaluate possible lagged effects.

Legal entity responsible for the study

Albino Oliveira-Maia.

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 777167.

Disclosure

F. Cardoso: Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Amgen; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Astellas/Medivation; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: AstraZeneca; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Celgene; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Daiichi Sankyo; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Eisai; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: GE oncology; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Genentech; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results.: GlaxoSmithKline; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results.: Macrogenics; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Medscape; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Merck-Sharp; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Merus BV; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Mylan; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Mundipharma; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Novartis; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Pfizer; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Pierre Fabre; Advisory/Consultancy, The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: prIME Oncology; Advisory/Consultancy, The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing, or in the decision to publish the results: Roche, Samsung Bioepis, Sanofi, Seagen, Teva. A. Oliveira-Maia: Research grant/Funding (self), A grant for norming and validation of cognitive tests: Schuhfried GmBH; Leadership role, National coordinator for Portugal of a Non-interventional Study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe: Janssen-Cilag Ltd.; Research grant/Funding (self), A trial of psilocybin therapy for treatment-resistant depression: Compass Pathways, Ltd. All other authors have declared no conflicts of interest.

Collapse